These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 8835104)

  • 21. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.
    Flynn CM; Johnson DM; Jones RN
    J Chemother; 1996 Dec; 8(6):411-5. PubMed ID: 8981179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.
    Lang BJ; Aaron SD; Ferris W; Hebert PC; MacDonald NE
    Am J Respir Crit Care Med; 2000 Dec; 162(6):2241-5. PubMed ID: 11112146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P; Hasçelik G; Unal S
    Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pomegranate pericarp extract enhances the antibacterial activity of ciprofloxacin against extended-spectrum β-lactamase (ESBL) and metallo-β-lactamase (MBL) producing Gram-negative bacilli.
    Dey D; Debnath S; Hazra S; Ghosh S; Ray R; Hazra B
    Food Chem Toxicol; 2012 Dec; 50(12):4302-9. PubMed ID: 22982804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Synergistic activity between ticarcillin, azlocillin, cefsulodin, ceftazidime and tobramycin or amikacin against Pseudomonas aeruginosa (author's transl)].
    Petit JC; Richard G; Burghoffer B; Daguet GL
    Pathol Biol (Paris); 1982 Jun; 30(6):426-31. PubMed ID: 6810286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postantibiotic effect and virulence factors depression induced by ciprofloxacin and by aminoglycosides in a clinical isolate of Pseudomonas aeruginosa.
    Hostacka A
    Zentralbl Bakteriol; 1996 Mar; 283(3):322-7. PubMed ID: 8861870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibacterial activity of gentamicin and ciprofloxacin against Gram-negative bacteria: interactions with pig and calf sera.
    Miglioli PA; Silini R; Carzeri O; Grabocka E; Allerberger F
    Pharmacol Res; 1999 Apr; 39(4):321-3. PubMed ID: 10208763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa.
    Zuravleff JJ; Yu VL; Yee RB
    J Lab Clin Med; 1983 Jun; 101(6):896-902. PubMed ID: 6406628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ciprofloxacin in combination with other antimicrobial substances].
    Shah PM; Mellinghoff D; Stille W
    Arzneimittelforschung; 1988 Mar; 38(3):411-5. PubMed ID: 3164186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Synthesis and antibacterial activity of N-(aroylalkyl) ciprofloxacin].
    Hu AX; Wang YT; You TB
    Yao Xue Xue Bao; 2007 Aug; 42(8):854-7. PubMed ID: 17944234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of synergistic interactions of danofloxacin and orbifloxacin against quinolone-resistant Escherichia coli isolated from animals by the checkerboard and time-kill methods.
    Cengiz M; Sahinturk P
    J Antibiot (Tokyo); 2013 Oct; 66(10):629-31. PubMed ID: 23778116
    [No Abstract]   [Full Text] [Related]  

  • 32. Selection of cross-resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime.
    Alyaseen SA; Piper KE; Rouse MS; Steckelberg JM; Patel R
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2543-5. PubMed ID: 15917569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of Smith's quinolone killing mechanisms during the PAE of ciprofloxacin on Escherichia coli.
    Wickens HJ; Pinney RJ
    Int J Pharm; 2001 Oct; 227(1-2):149-56. PubMed ID: 11564549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation in the content of ciprofloxacin susceptibility testing discs: its effect on the BSAC disc method.
    Darville JM; Lovering AM
    J Antimicrob Chemother; 2003 Feb; 51(2):465-7. PubMed ID: 12562726
    [No Abstract]   [Full Text] [Related]  

  • 35. Interaction between ciprofloxacin and metal cations: its influence on physicochemical characteristics and antibacterial activity.
    Li RC; Nix DE; Schentag JJ
    Pharm Res; 1994 Jun; 11(6):917-20. PubMed ID: 7937536
    [No Abstract]   [Full Text] [Related]  

  • 36. Zinc can counteract selection for ciprofloxacin resistance.
    Vos M; Sibleyras L; Lo LK; Hesse E; Gaze W; Klümper U
    FEMS Microbiol Lett; 2020 Feb; 367(3):. PubMed ID: 32105320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The loss of antibiotic activity of ciprofloxacin by photodegradation.
    Phillips G; Johnson BE; Ferguson J
    J Antimicrob Chemother; 1990 Dec; 26(6):783-9. PubMed ID: 2081719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decimal assay for additivity of drugs permits delineation of synergy and antagonism.
    Sanders CC; Sanders WE; Moland ES
    Antimicrob Agents Chemother; 1993 Feb; 37(2):260-4. PubMed ID: 8452356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions with ciprofloxacin and erythromycin leading to aminophylline toxicity.
    Andrews PA
    Nephrol Dial Transplant; 1998 Apr; 13(4):1006-8. PubMed ID: 9568870
    [No Abstract]   [Full Text] [Related]  

  • 40. Activity of ciprofloxacin against Escherichia coli phagocytosed by monocytes and macrophages.
    Burgaleta C; Moreno T; Loza E
    J Antimicrob Chemother; 1989 Mar; 23(3):460-2. PubMed ID: 2659568
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.